supernus pharmaceuticals inc
(SUPN:NASDAQ GM)
supernus pharmaceuticals inc (SUPN) Snapshot
|
Open
$6.64
|
Previous Close
$6.65
|
|
|
Day High
$6.90
|
Day Low
$6.56
|
|
|
52 Week High
07/19/12 - $16.68
|
52 Week Low
06/5/12 - $4.30
|
|
|
Market Cap
212.6M
|
Average Volume 10 Days
1.3M
|
|
|
EPS TTM
$-2.27
|
Shares Outstanding
31.0M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
supernus pharmaceuticals inc (SUPN) Related Businessweek News
No Related Businessweek News Foundsupernus pharmaceuticals inc (SUPN) Details
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
supernus pharmaceuticals inc (SUPN) Top Compensated Officers
supernus pharmaceuticals inc (SUPN) Key Developments
Supernus Pharmaceuticals, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2013. For the quarter, the company reported revenues of $147,000 against $208,000 a year ago. Operating loss was $17,908,000 against $7,878,000 a year ago. Net loss was $18,414,000 against $9,277,000 a year ago. Net loss attributable to common shareholders was $18,414,000 or $0.60 per basic and diluted sharer against $10,135,000 or $6.05 per basic and diluted sharer a year ago. For the year 2013, In order to support both product launches and the continued development of the company's pipeline, the company projected cash burn for 2013 to range from $85 million to $95 million. The decrease of $10 million in projected cash burn from prior projection of $95 million to $105 million is primarily due to the refinancing of secured credit facility.
Supernus Pharmaceuticals, Inc., Q1 2013 Earnings Call, May 13, 2013
Supernus Pharmaceuticals, Inc. announced that they will report Q1, 2013 results After-Market on May 13, 2013
| Recently Viewed | |||
| SUPN:US | $6.86 USD | +0.21 |  |
| Company | Last | Change | |
| No competitor information is available for SUPN. | |||
| View Industry Companies | |||
Industry Analysis
SUPN
Industry Average
| Valuation | SUPN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 144.7x |
|
| Price/Book | 5.0x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 81.8x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact SUPERNUS PHARMACEUTICALS INC, please visit www.supernus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
